Articles

P12 The glycan-binding galectin-1 is involved in osteoclast biology

BJH - volume 8, issue Abstract Book BHS, february 2017

J. Muller MSc, M. Binsfeld , S. Dubois , G. Carmeliet , Y. Beguin MD, PhD, R. Heusschen PhD, J. Caers MD, PhD

Read more

O.5 Sequential administration of 5-azacytidine (AZA) and donor lymphocyte infusion (DLI) for patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) in relapse after allogeneic stem cell transplantation (SCT): an interim analysis from the Belgian Hematology Society (BHS)

BJH - volume 8, issue Abstract Book BHS, february 2017

X. Poiré MD, PhD, C. Graux MD, PhD, A. Ory , J. Jamart , F. Frédéric , H. Schoemans MD, PhD, P. Lewalle MD, PhD, A. De Becker MD, D. Deeren MD, Z. Berneman MD, PhD, T. Kerre MD, PhD, P. Zachée MD, PhD, D. Selleslag MD, Y. Beguin MD, PhD

Read more

PP05 The detection rate of PET/CT after co-administration of [18F]NaF and [18F]FDG is superior to the detection rate of whole-body MRI in the diagnosis of MM lesions

BJH - volume 8, issue Abstract Book BHS, february 2017

J. Caers MD, PhD, N. Withofs MD, PhD, F. Cousin , T. Tancredi , P. Simoni , B. De Prijck MD, K. Hafraoui , C. Bonnet MD, R. Heusschen PhD, V. Alvarez-Miezentseva , R. Hustinx , Y. Beguin MD, PhD

Read more

PP50 Comparison of xenogeneic graft-versus-host reactions in humanized NSG and NSG-HLA-A2/HHD mice

BJH - volume 8, issue Abstract Book BHS, february 2017

G. Ehx , G. Fransolet , L. Delens , J. Muller MSc, Y. Beguin MD, PhD, S. Humblet-Baron , M. Hannon , prof. F. Baron

Read more

PP71 Impact of Tofacitinib on xenogeneic graft versus host disease

BJH - volume 8, issue Abstract Book BHS, february 2017

M. Hannon , C. Grégoire MD, J. Muller MSc, G. Fransolet , L. Delens , Y. Beguin MD, PhD, G. Ehx , prof. F. Baron

Read more

PP74 Limited impact of imatinib in a murine model of sclerodermatous chronic graft-versus-host disease

BJH - volume 8, issue Abstract Book BHS, february 2017

G. Fransolet , L. Belle , J. Somja MD, PhD, M. Binsfeld , P. Delvenne , P. Drion , M. Hannon , Y. Beguin MD, PhD, G. Ehx , prof. F. Baron

Read more

Multipotent mesenchymal stromal cell therapy for steroid-refractory acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation

BJH - volume 7, issue 6, december 2016

S. Servais MD, PhD, C. Grégoire MD, prof. F. Baron , E. Willems MD, PhD, A. Briquet PhD, E. Baudoux MD, O. Delloye PhD, O. Giet PhD, C. Lechanteur PhD, Y. Beguin MD, PhD

Summary

Steroid-refractory acute graft-versus-host disease is a severe complication after allogeneic stem cell transplantation. So far, its treatment remains very challenging since the current therapies do not offer significant benefits. Among the most recent approaches, multipotent mesenchymal stromal cell-based therapy has attracted great interest over the past decade. Here, we briefly reviewed the current knowledges about the immunomodulatory properties of multipotent mesenchymal stromal cells as well as results of preclinical and clinical studies having assessed their efficacy to modulate steroid-refractory acute graft-versus-host disease.

(BELG J HEMATOL 2016;7(6):229–35)

Read more